HAEGT

CAS No. 852155-81-8

HAEGT( —— )

Catalog No. M30080 CAS No. 852155-81-8

HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 425 Get Quote
10MG 608 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    HAEGT
  • Note
    Research use only, not for human use.
  • Brief Description
    HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.
  • Description
    HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.
  • In Vitro
    HAEGT (0-500 μM) is a competitive substrate for probing prime substrate binding sites of human dipeptidyl peptidase-IV (DPP-IV).HAEGT can be catalyzed cleavage by DPP-IV with a km value of 38 μM, Kcat value of 3.1 S-1.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    852155-81-8
  • Formula Weight
    513.5
  • Molecular Formula
    C20H31N7O9
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:His-Ala-Glu-Gly-Thr

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • HAEGTFTSD

    HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.

  • LGD-6972

    LGD-6972 (RVT 1502) is a novel potent, selective, orally bioavailable glucagon receptor (GCGR) antagonist.

  • Retatrutide

    Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.